Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial

References

• Abegunde DO, Mathers CD, Adam T, et al. Chronic diseases 1 – The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370:1929–1938.
   PubMed Web of Science ®Google Scholar
• Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu Rev Public Health. 2005;26:1–35.
   PubMed Web of Science ®Google Scholar
• Yach D, Hawkes C, Gould CL, et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global status report on noncommunicable diseases. Geneva, Switzerland: WHO; 2014.
   Google Scholar
• Ball J, Thompson DR, Ski CF, et al. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust. 2015;202:32–35.
   PubMed Web of Science ®Google Scholar
• Ball J, Carrington MJ, McMurray JJV, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–1824.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Roth GA, Gillum RF, et al. Global burden of atrial fibrillation in developed and developing nations. Global Heart. 2014;9:113–119.
   PubMedGoogle Scholar
• Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med. 2012;172:739–741.
   PubMedGoogle Scholar
• Camm AJ, Savelieva I, Potpara T, et al. The changing circumstance of atrial fibrillation – progress towards precision medicine. J Intern Med. 2016;279:412–427.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Essebag V. Economic burden of atrial fibrillation: implications for intervention. Am J Pharm Benefits. 2012;4:58–65.
   Google Scholar
• Johnsen SP, Dalby LW, Tackstrom T, et al. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017;17:714.
   PubMed Web of Science ®Google Scholar
• Mays GP, Au M, Claxton G. MARKETWATCH: convergence and dissonance: evolution in private-sector approaches to disease management and care coordination. Health Affair. 2007;26:1683–1691.
   Web of Science ®Google Scholar
• Bodenheime T. Disease management in the American market. BMJ. 2000;320:563–566.
   PubMedGoogle Scholar
• Ellrodt G, Cook DJ, Lee J, et al. Evidence-based disease management. JAMA. 1997;278:1687–1692.
   PubMed Web of Science ®Google Scholar
• Todd W, Nash D, editors. Disease Management: A Systems Approach to Improving Patient Outcomes. San Francisco, CA: Jossey Bass; 2001.
   Google Scholar
• Maru S, Byrnes J, Whitty JA, et al. Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs. Eur J Cardiovasc Nur. 2015;14:26–33.
   PubMed Web of Science ®Google Scholar
• Maru S, Byrnes J, Carrington MJ, et al. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort — The WHICH? study (which heart failure intervention is most cost-effective & consumer friendly in reducing hospital care). Int J Cardiol. 2015;201:368–375.
   PubMed Web of Science ®Google Scholar
• Stewart S, Ball J, Horowitz JD, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385:775–784.
   PubMed Web of Science ®Google Scholar
• Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:1223–1226.
   Google Scholar
• Carrington MJ, Ball J, Horowitz JD, et al. Navigating the fine line between benefit and risk in chronic atrial fibrillation: rationale and design of the standard versus atrial fibrillation specific management study (SAFETY). Int J Cardiol. 2013;166:359–365.
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015.
   Google Scholar
• Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, version 4.5. Canberra, Australia: Commonwealth of Australia; 2015.
   Google Scholar
• Medical Services Advisory Committee. Technical guidelines for preparing assessment reports for the Medical Services Advisory Committee Version 2.0. Canberra, Australia: Commonwealth of Australia; 2016.
   Google Scholar
• Independent Hospital Pricing Authority. National Efficient Price Determination 2016–17. Canberra, Australia: Commonwealth of Australia; 2016.
   Google Scholar
• Department of Health. Medicare Benefits Schedule Book. Canberra, Australia: Commonwealth of Australia; 2016.
   Google Scholar
• Department of Health. Schedule of Pharmaceutical Benefits. Canberra, Australia: Commonwealth of Australia; 2016.
   Google Scholar
• Australian Bureau of Statistics. Consumer Price Index, Australia. 2016. Available from: http://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage/6401.0Jun%202016?OpenDocument [Accessed 29 March 2018].
   Google Scholar
• Kularatna S, Whitty JA, Johnson NW, et al. A comparison of health state utility values associated with oral potentially malignant disorders and oral cancer in Sri Lanka assessed using the EQ-5D-3 L and the EORTC-8D. Health Qual Life Outcomes. 2016;14:101.
   PubMed Web of Science ®Google Scholar
• Viney R, Norman R, King MT, et al. Time trade-off derived EQ-5D weights for Australia. Value Health. 2011;14:928–936.
   PubMed Web of Science ®Google Scholar
• Independent Hospital Pricing Authority. National Hospital Cost Data Collection Australian Public Hospitals Cost Report 2012–2013, Round 17. Canberra, Australia: Commonwealth of Australia; 2015.
   Google Scholar
• Katzenellenbogen JM, Teng THK, Lopez D, et al. Initial hospitalisation for atrial fibrillation in Aboriginal and non-Aboriginal populations in Western Australia. HEART. 2015;101:712–719.
   PubMed Web of Science ®Google Scholar
• Price Water House Coopers. The economic costs of atrial fibrillation in Australia. Canberra, Australia; 2010.
   Google Scholar
• Heniks J, Tomini F, van Asselt T, et al. Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace. 2013;15:1128–1135.
   PubMed Web of Science ®Google Scholar
• Inglis S, McLennan S, Dawson A, et al. A new solution for an old problem? Effects of a nurse-led, multidisciplinary, home-based intervention on readmission and mortality in patients with chronic atrial fibrillation. J Cardiovasc Nurs. 2004;19:118–127.
   PubMedGoogle Scholar